Immunovant Inc IMVT

NAS: IMVT | ISIN: US45258J1025   1/05/2025
15,90 USD (-1,55%)
(-1,55%)   1/05/2025
Grafiek Immunovant Inc Grafiek Immunovant Inc

Immunovant Inc in het nieuws

13 oktober 2023 · Thinking about trading options or stock in Dollar General, Immunovant, Camber Energy, Advanced Micro Devices, or Novo Nordisk? · Persbericht

28 september 2023 · Thinking about buying stock in Seelos Therapeutics, West Red Lake Gold Mines, Immunovant, MSP Recovery, or Transcode Therapeutics? · Persbericht

27 september 2023 · Thinking about buying stock in American Lithium, Avalo Therapeutics, Seelos Therapeutics, Rivian Automotive, or Immunovant? · Persbericht

26 september 2023 · Thinking about trading options or stock in Immunovant, Manchester United, Philip Morris International, Vale SA, or Novo Nordisk? · Persbericht

5 oktober 2022 · R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing · Persbericht

19 april 2021 · APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc. · Persbericht

19 maart 2021 · Pomerantz Law Firm Announces the Filing of a Class Action against Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation and Certain Officers - IMVT; HSACU; HSAC; and HSACW · Persbericht

18 maart 2021 · SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW · Persbericht

18 maart 2021 · IMVT SHAREHOLDER LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc. · Persbericht

17 maart 2021 · INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Immunovant, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm · Persbericht

Profiel Immunovant Inc

Biotechnologie
Financiële Conglomeraten
Financiën
Gezondheidstechnologie

Werknemers: 144

Mijn selecties